Ligand Pharmaceuticals Inc (NAS:LGND)
$ 81.36 -1.01 (-1.23%) Market Cap: 1.46 Bil Enterprise Value: 1.16 Bil PE Ratio: 15.29 PB Ratio: 1.81 GF Score: 76/100

Q4 2018 Ligand Pharmaceuticals Inc Earnings Call Transcript

Feb 07, 2019 / 09:30PM GMT
Release Date Price: $72.66 (-0.95%)
Operator

Good afternoon, and welcome to the Ligand Fourth Quarter Earnings Call. My name is Vincent, and I'll be facilitating the audio portion of today's interactive broadcast. (Operator Instructions)

I'll now turn the call over to your speaker today, Mr. Todd Pettingill. Sir, you may begin.

Todd Pettingill
Ligand Pharmaceuticals Incorporated - Director of Corporate Development

Welcome to Ligand's Fourth Quarter of 2018 Financial Results and Business Update Conference Call. Speaking today for Ligand are John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.

As a reminder, today's call will contain forward-looking statements within the meaning of federal securities laws. These may include but are not limited to statements regarding intent, belief or current expectations of the company and its management regarding its internal and partnered programs. These statements involve risks and uncertainties, and actual events or results may differ materially from the projections described in today's press release and this conference call.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot